KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$8.54
+3.26%Sep 3, 2026, 20:01 UTC
Kamada Ltd. obtained a tax ruling from the Israel Tax Authority regarding its previously announced cash dividend of $0.17 per share, totaling approximately $9.8 million, to be paid on September 17, 2026.
Source:Aug 17, 2026, 11:00 UTC
Kamada declared a cash dividend of $0.17 per share, to be paid consistent with its cash dividend policy, alongside reporting record-high revenue and profitability for the first six months of 2026.
Source:Aug 12, 2026, 11:05 UTC
Kamada Ltd. reported record-high financial results for the second quarter and first half of 2026, with double-digit profitable growth, and affirmed its 2026 annual guidance.
Aug 12, 2026, 11:00 UTC
Kamada Ltd. announced that CFO Chaime Orlev will transition out of his role effective December 31, 2026, with a search underway for a successor.
Source:Jul 20, 2026, 11:00 UTC
Kamada Ltd. announced a three-year $50 million sales agreement to supply plasma to a leading biopharmaceutical company focused on plasma-derived therapies.
Source:Jun 1, 2026, 11:00 UTC
Kamada Ltd. received FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory.
Source: